$10.68
EyePoint Pharmaceuticals
Performance
Dividends
33%
1W
1M
YTD
1Y
3Y
14/36
Growth Score
9/36
Dividend Score
Valuation
PE Ratio
-5.07
PS Ratio
13.11
RSI
-
3
PEG Ratio
0.02
0
PRG Ratio
-0.1
PDG Ratio
0
Growth
011%0-6%0-5%0-52%
31%-85%-46%27%
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule of 40
88.61%
3
Gross Margin
93.29%
3
Current Ratio
7.85
Return on Assets
-40.48%
Return on Equity
-54.27%
Return on inv. Capital
-50.04%
Institutional Holder
75.925.328076.100.793
1142139
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 43.27M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 -130.87M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 39.56M
2018
2019
2020
2021
2022
2023
2024
6
Events
EYPT
EyePoint Pharmaceuticals
in 283 days
before market open
Earnings per Share is expected with - and revenue with - .
EYPT
EyePoint Pharmaceuticals
in 220 days
before market open
Earnings per Share is expected with - and revenue with - .
EYPT
EyePoint Pharmaceuticals
in 102 days
before market open
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Healthcare
Biotechnology
IPO Date
27.01.2005
MaketCap
734.56M
Country
US
CEO
Jay S. Duker
Description
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
Updated 21.07.2025